title: [Treatment of crow's feet with two different botulinum toxin type A preparations in split-face technique].
abstract: BACKGROUND
  For the first time, the effectiveness of Xeomin®, and Dysport® in an dose-ratio of 1:3 treating crow's feet (FWS 2-3) was evaluated in a double-blind randomized pilot study.
  
  
  METHODS
  Xeomin® (12 units) was compared to Dysport® (36 units) in an intra-individual split-face technique in 22 patients over a period of 4 months. According to the facial-wrinkle-scale (FWS) patients were rated as responders with an improvement of at least 1 point in FWS.
  
  
  RESULTS
  One month after treatment significantly more than 80% of patients were rated as responders. The different products proved to be equivalent in response rate and effectiveness with no significant difference after 4 weeks and 4 months in statistical analysis. Surprisingly the decrease in FWS of crows' feet at rest was more pronounced.
  
  
  CONCLUSIONS
  The different botulinum toxin type A formulations proved to be equivalent in effectiveness and tolerability in a dose ratio of 1:3 (Xeomin®: Dysport®) The more pronounced decrease of crow's feet at rest points out the importance of muscle insertion into the skin for the cosmetic result in the periorbital region.
authors.affiliation: Dermatologikum Hamburg, Stephansplatz 5, Hamburg, Germany. prager@dermatologikum.de
authors.forename: W
authors.initials: W
authors.lastname: Prager
authors.forename: E
authors.initials: E
authors.lastname: Wissmüller
authors.forename: B
authors.initials: B
authors.lastname: Kollhorst
authors.forename: A
authors.initials: A
authors.lastname: Böer
authors.forename: I
authors.initials: I
authors.lastname: Zschocke
mesh_terms: D000328:Adult; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000627:therapeutic use; D012867:Skin / Q000033:anatomy & histology* / Q000187:drug effects*; D015595:Skin Aging / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A